Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial.

Saved in:
Bibliographic Details
Title: Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial.
Authors: Wijsenbeek MS; Center of Expertise for Interstitial Lung Diseases, Department of Respiratory Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands m.wijsenbeek-lourens@erasmusmc.nl., Assassi S; Division of Rheumatology, McGovern Medical School, UTHealth Houston, Houston, TX, USA., Azuma A; Clinical Research Center, Mihara General Hospital, Saitama, Japan.; Nippon Medical School, Tokyo, Japan., Cottin V; National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, UMR 754, ERN-LUNG, Lyon, France., Hoffmann-Vold AM; Department of Rheumatology, Oslo University Hospital, Oslo, Norway.; Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Maher TM; Department of Pulmonary, Critical Care and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.; Section of Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK., Martinez FJ; University of Massachusetts (UMass) Chan Medical School/UMass Memorial Health System, Worcester, MA, USA., Oldham JM; Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA., Richeldi L; Unità Operativa Complessa di Pneumologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy., Valenzuela C; Pulmonology Department, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Madrid, Spain., Gu H; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA., Ritter I; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany., Stowasser S; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany., Kreuter M; Center for Pulmonary Medicine, Department of Pneumology, Mainz University Medical Center and Pulmonary, Critical Care and Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany.
Corporate Authors: FIBRONEER-ILD Trial Investigators
Source: The European respiratory journal [Eur Respir J] 2026 Jul 09; Vol. 68 (1). Date of Electronic Publication: 2026 Jul 09 (Print Publication: 2026).
Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: European Respiratory Society Country of Publication: England NLM ID: 8803460 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 1399-3003 (Electronic) Linking ISSN: 09031936 NLM ISO Abbreviation: Eur Respir J Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1399-3003
DOI:10.1183/13993003.01899-2025